MedTrace Logo

Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

NCT02115308 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to measure the changes in cardiac function during a Lexiscan pharmacologic stress test using cardiac magnetic resonance imaging test.

Conditions

Interventions

DRUG

Regadenoson

Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.

Sponsors & Collaborators

  • Saint Luke's Health System

    collaborator OTHER

  • Saint Luke's Cardiovascular Consultants

    collaborator OTHER

  • Timothy M. Bateman

    lead OTHER

Principal Investigators

  • Timothy M Bateman, MD · Aspire Foundation

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-03
Primary Completion
2018-01-16
Completion
2018-03-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115308 on ClinicalTrials.gov